BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review
BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. The company's major product areas include baby and child gut health, adult gut health, probiotic gastrointestinal health, oral health and bone health. BioGaia's products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults and controls digestive problems such as colic, regurgitation, diarrhoea and constipation. The company' sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.
BioGaia AB Key Recent Developments
Feb 12,2021: MetaboGen has reached a new crucial milestone in its development of novel probiotic products
Feb 04,2021: BioGaia announces year-end report 2020
Oct 23,2020: BioGaia: Interim management statement January – September 2020
Oct 12,2020: BioGaia: Reduced sales due to covid-19
Aug 13,2020: BioGaia: Interim Report January – June 2020
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. The company's major product areas include baby and child gut health, adult gut health, probiotic gastrointestinal health, oral health and bone health. BioGaia's products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults and controls digestive problems such as colic, regurgitation, diarrhoea and constipation. The company' sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.
BioGaia AB Key Recent Developments
Feb 12,2021: MetaboGen has reached a new crucial milestone in its development of novel probiotic products
Feb 04,2021: BioGaia announces year-end report 2020
Oct 23,2020: BioGaia: Interim management statement January – September 2020
Oct 12,2020: BioGaia: Reduced sales due to covid-19
Aug 13,2020: BioGaia: Interim Report January – June 2020
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
List of Tables
List of Figures
SECTION 1 - ABOUT THE COMPANY
BioGaia AB - Key Facts
BioGaia AB - Key Employees
BioGaia AB - Key Employee Biographies
BioGaia AB - Major Products and Services
BioGaia AB - History
BioGaia AB - Company Statement
BioGaia AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
BioGaia AB - Business Description
Business Segment: Adult Health
Overview
Performance
Business Segment: Other
Overview
Performance
Business Segment: Paediatrics
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: EMEA
Performance
R&D Overview
BioGaia AB - Corporate Strategy
BioGaia AB - SWOT Analysis
SWOT Analysis - Overview
BioGaia AB - Strengths
BioGaia AB - Weaknesses
BioGaia AB - Opportunities
BioGaia AB - Threats
BioGaia AB - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioGaia AB, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 12, 2021: MetaboGen has reached a new crucial milestone in its development of novel probiotic products
Feb 04, 2021: BioGaia announces year-end report 2020
Oct 23, 2020: BioGaia: Interim management statement January – September 2020
Oct 12, 2020: BioGaia: Reduced sales due to covid-19
Aug 13, 2020: BioGaia: Interim Report January – June 2020
May 07, 2020: BioGaia Interim Management Statement 1 January – 31 March 2020
Mar 30, 2020: BioGaia update concerning COVID-19 pandemic
Feb 06, 2020: BioGaia – Year-end report 2019
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
List of Figures
SECTION 1 - ABOUT THE COMPANY
BioGaia AB - Key Facts
BioGaia AB - Key Employees
BioGaia AB - Key Employee Biographies
BioGaia AB - Major Products and Services
BioGaia AB - History
BioGaia AB - Company Statement
BioGaia AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
BioGaia AB - Business Description
Business Segment: Adult Health
Overview
Performance
Business Segment: Other
Overview
Performance
Business Segment: Paediatrics
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: EMEA
Performance
R&D Overview
BioGaia AB - Corporate Strategy
BioGaia AB - SWOT Analysis
SWOT Analysis - Overview
BioGaia AB - Strengths
BioGaia AB - Weaknesses
BioGaia AB - Opportunities
BioGaia AB - Threats
BioGaia AB - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioGaia AB, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 12, 2021: MetaboGen has reached a new crucial milestone in its development of novel probiotic products
Feb 04, 2021: BioGaia announces year-end report 2020
Oct 23, 2020: BioGaia: Interim management statement January – September 2020
Oct 12, 2020: BioGaia: Reduced sales due to covid-19
Aug 13, 2020: BioGaia: Interim Report January – June 2020
May 07, 2020: BioGaia Interim Management Statement 1 January – 31 March 2020
Mar 30, 2020: BioGaia update concerning COVID-19 pandemic
Feb 06, 2020: BioGaia – Year-end report 2019
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
BioGaia AB, Key Facts
BioGaia AB, Key Employees
BioGaia AB, Key Employee Biographies
BioGaia AB, Major Products and Services
BioGaia AB, History
BioGaia AB, Other Locations
BioGaia AB, Subsidiaries
BioGaia AB, Key Competitors
BioGaia AB, Ratios based on current share price
BioGaia AB, Annual Ratios
BioGaia AB, Annual Ratios (Cont...1)
BioGaia AB, Annual Ratios (Cont...2)
BioGaia AB, Interim Ratios
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioGaia AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
BioGaia AB, Key Facts
BioGaia AB, Key Employees
BioGaia AB, Key Employee Biographies
BioGaia AB, Major Products and Services
BioGaia AB, History
BioGaia AB, Other Locations
BioGaia AB, Subsidiaries
BioGaia AB, Key Competitors
BioGaia AB, Ratios based on current share price
BioGaia AB, Annual Ratios
BioGaia AB, Annual Ratios (Cont...1)
BioGaia AB, Annual Ratios (Cont...2)
BioGaia AB, Interim Ratios
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioGaia AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
BioGaia AB, Performance Chart (2016 - 2020)
BioGaia AB, Ratio Charts
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
COMPANIES MENTIONED
Probi AB
Kaneka Corp
Evolve Biosystems Inc
Essum AB
ADM Protexin Ltd
BioGaia AB, Performance Chart (2016 - 2020)
BioGaia AB, Ratio Charts
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
COMPANIES MENTIONED
Probi AB
Kaneka Corp
Evolve Biosystems Inc
Essum AB
ADM Protexin Ltd